Paradigm’s Kurt Mussina discusses why scale should drive operational efficiency, not consolidation into single-site studies.
Kurt Mussina
Advertisement
Kurt Mussina is CEO of Paradigm Clinical Research. With nearly 40 years of experience across clinical research, CRO, CDMO, and biopharmaceutical industries, Kurt has built and scaled organizations, driven profitable growth, and fostered long-term relationships with sponsors, CROs, and the broader clinical research community.
Articles by Kurt Mussina
Paradigm’s Kurt Mussina touches on why he rejects the “site management organization” model in favor of one unified business.
The redundancy of process and documentation for activating trial sites has been an issue in the past as it can lead to delays in trial initiation. Rapid study startup can illuminate these inefficiencies by removing or reducing non-value tasks.
Advertisement
Latest Updated Articles
- Rapid Study Startup: Streamlining Trial Site Activation
February 17th 2017
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
What It Actually Means to Embed AI Across the Clinical Operating Model
2
Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection
3
2026 SCRS Global Site Solutions Summit: What Should Sponsors and CROs Change About How They Contract with a Network?
4
2026 SCRS Global Site Solutions Summit: What Does Al-Assisted Patient Matching Look Like?
5